论文部分内容阅读
目的对紫杉醇加洛铂治疗晚期非小细胞肺癌的疗效及安全性予以评价。方法选取78例晚期非小细胞肺癌者且参考随机数字表法按照1∶1比例将其分为紫杉醇加洛铂化疗组(观察组)和紫杉醇联合顺铂化疗组(对照组),同时给予两组患者相应化疗方案且对化疗效果、不良事件发生情况进行观察和数据的统计学处理分析。结果观察组和对照组化疗有效率、临床受益率分别相比差异无统计学意义,▲P>0.05;观察组患者白细胞数量降低、血小板数量下降、肾功能损伤、恶心、呕吐不良事件发生率低于对照组▲P<0.05,而腹痛与腹泻相比无差异◆P>0.05。结论紫杉醇加洛铂治疗晚期非小细胞肺癌效果显著且安全可靠,值得临床推广应用。
Objective To evaluate the efficacy and safety of paclitaxel plus lobaplatin in the treatment of advanced non-small cell lung cancer. Methods Seventy - eight patients with advanced non - small cell lung cancer were enrolled in this study. They were divided into paclitaxel plus carlobacl chemotherapy group (observation group) and paclitaxel plus cisplatin chemotherapy group (control group) according to a 1: 1 ratio by random number table. The patients in the corresponding chemotherapy regimens and chemotherapy, adverse events were observed and the data were analyzed statistically. Results There was no significant difference in the rate of chemotherapy and clinical benefit between the observation group and the control group (P> 0.05). The number of white blood cells, the number of platelets, the number of renal dysfunction, the incidence of nausea and vomiting were lower in observation group In the control group ▲ P <0.05, while no difference in abdominal pain and diarrhea ◆ P> 0.05. Conclusion paclitaxel plus paluo platinum in the treatment of advanced non-small cell lung cancer is significant and safe and reliable, worthy of clinical application.